Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$8.71 USD
+0.09 (1.04%)
Updated Aug 9, 2024 04:00 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VIR 8.71 +0.09(1.04%)
Will VIR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VIR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VIR
Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High?
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
VIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
Other News for VIR
Vidrala Continues Share Buyback Program
Vidrala Executes Share Buyback Program Trades
Breaking Down Vir Biotechnology: 6 Analysts Share Their Views
Morgan Stanley Sticks to Its Hold Rating for Vir Biotechnology (VIR)
Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG), Regeneron (REGN) and Vir Biotechnology (VIR)